Effect of fenoldopam on the aldosterone response to metoclopramide in man.
The effect of fenoldopam, a selective DA1-agonist, on the plasma aldosterone response to metoclopramide was studied in six hypertensive patients included in a multicentre double-blind placebo controlled cross-over study of the antihypertensive effects of fenoldopam. Fenoldopam significantly increased baseline plasma renin activity (PRA); baseline plasma aldosterone levels rose slightly. Baseline PRL and the PRL response to metoclopramide were not altered by fenoldopam. After metoclopramide, a significant increase of plasma aldosterone was observed during treatment with fenoldopam, as well as in the placebo-period. The peak values were not significantly different and occurred at 15 min during both treatment periods. These results indicate that fenoldopam does not reduce metoclopramide-induced aldosterone secretion and therefore suggest that the adrenal dopamine receptor is not identical to the vascular DA1 receptor.
Dupont
A G
AG
Vanderniepen
P
P
Volckaert
A
A
Smitz
J
J
Vansteirteghem
A C
AC
Six
R O
RO
D000450:Aldosterone / Q000097:blood / Q000378:metabolism*; D001552:Benzazepines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D018818:Fenoldopam; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008787:Metoclopramide / Q000494:pharmacology*; D008875:Middle Aged; D011897:Random Allocation; D012083:Renin / Q000097:blood; D013997:Time Factors
D001552:Benzazepines; D000450:Aldosterone; D012083:Renin; D018818:Fenoldopam; D008787:Metoclopramide